New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
19:03 EDTMNOVMedicNova receives notice of allowance for new patent covering MN-001, MN-002
MediciNova announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 and MN-002 for the treatment of nonalcoholic fatty liver disease. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than December 2032. The allowed claims cover a method of treating nonalcoholic fatty liver disease and a method of reducing liver inflammation in nonalcoholic fatty liver disease using MN-001 or MN-002. The allowed claims cover oral administration, including tablets and capsules, as well as liquid dosage forms.
News For MNOV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 16, 2015
18:14 EDTMNOVMediciNova says MN-166 trial enrolled 30 of 60 subjects
MediciNova announced that the ongoing clinical trial of MN-166 in amyotrophic lateral sclerosis has enrolled 30 of the 60 subjects planned for participation. The trial is a randomized, double-blind, placebo-controlled study which includes a six-month treatment period followed by a six-month open-label extension. The study is evaluating several efficacy endpoints including functional activity, respiratory function, muscle strength, and non-invasive ventilation utilization in addition to monitoring the safety and tolerability of MN-166 60 mg/day versus placebo when administered in combination with riluzole in subjects with ALS.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use